J. Doorbar, N. Egawa, H. Griffin, C. Kranjec, and I. Murakami, Human papillomavirus molecular biology and disease association, Rev Med Virol, vol.25, issue.1, pp.2-23, 2015.

M. Scheffner, B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley, The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53, Cell, vol.63, pp.1129-1136, 1990.

K. Münger, M. Scheffner, J. M. Huibregtse, and P. M. Howley, Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products, Cancer Surv, vol.12, pp.197-217, 1992.

K. Huh, X. Zhou, H. Hayakawa, J. Y. Cho, T. A. Libermann et al., Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor, J Virol, vol.81, pp.9737-9747, 2007.

H. Zur-hausen, Human papillomaviruses in the pathogenesis of anogenital cancer, Virology, vol.184, pp.9-13, 1991.

E. Jacquin, A. Baraquin, R. Ramanah, X. Carcopino, A. Morel et al., Methylation of human papillomavirus Type 16 CpG sites at E2-binding site 1 (E2BS1), E2BS2, and the Sp1-binding site in cervical cancer samples as determined by high-resolution melting analysis-PCR, J Clin Microbiol, vol.51, pp.3207-3215, 2013.

C. Zhang, Z. Deng, X. Pan, T. Uehara, M. Suzuki et al., Effects of methylation status of CpG sites within the HPV16 long control region on HPV16-positive head and neck cancer cells, PLoS One, vol.10, p.141245, 2015.

M. Stich, L. Ganss, J. Puschhof, E. S. Prigge, M. Reuschenbach et al., -aza-2'-deoxycytidine (DAC) treatment downregulates the HPV E6 and E7 oncogene expression and blocks neoplastic growth of HPV-associated cancer cells, Oncotarget, vol.8, issue.5, pp.52104-52117, 2016.

A. Morel, A. Baguet, J. Perrard, C. Demeret, E. Jacquin et al., 5azadC treatment upregulates miR-375 level and represses HPV16 E6 expression, Oncotarget, vol.8, pp.46163-46176, 2017.
URL : https://hal.archives-ouvertes.fr/pasteur-01971566

H. M. Jung, B. L. Phillips, and E. K. Chan, activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14-3-3?, Mol Cancer, vol.13, p.80, 2014.

M. A. Schneider, K. D. Scheffer, T. Bund, F. Boukhallouk, C. Lambert et al., The transcription factors TBX2 and TBX3 interact with human papillomavirus 16 (HPV16) L2 and repress the long control region of HPVs, J Virol, vol.87, pp.4461-4474, 2013.

S. Wansleben, J. Peres, S. Hare, C. R. Goding, and S. Prince, T-box transcription factors in cancer biology, Biochim Biophys Acta, vol.1846, pp.380-391, 2014.

A. Abrahams, M. I. Parker, and S. Prince, The T-box transcription factor Tbx2: Its role in development and possible implication in cancer, IUBMB Life, vol.62, pp.92-102, 2010.

W. L. Du, Q. Fang, Y. Chen, J. W. Teng, Y. S. Xiao et al., Effect of silencing the T-Box transcription factor TBX2 in prostate cancer PC3 and LNCaP cells, Mol Med Rep, vol.16, pp.6050-6058, 2017.

A. Khalil, B. Dekmak, F. Boulos, J. Kantrowitz, A. Spira et al., Transcriptomic alterations in lung adenocarcinoma unveil new mechanisms targeted by the TBX2 subfamily of tumor suppressor genes, Front Oncol, vol.8, p.482, 2018.

A. A. Khalil, S. Sivakumar, F. Lucas, T. Mcdowell, W. Lang et al., TBX2 subfamily suppression in lung cancer pathogenesis: A high-potential marker for early detection, Oncotarget, vol.8, pp.68230-68241, 2017.

L. Rani, N. Mathur, R. Gupta, A. Gogia, G. Kaur et al., Genome-wide DNA methylation profiling integrated with gene expression profiling identifiesPAX9as a novel prognostic marker in chronic lymphocytic leukemia, Clin Epigenetics, vol.9, p.57, 2017.

S. A. Farkas, B. G. Sorbe, and T. K. Nilsson, Epigenetic changes as prognostic predictors in endometrial carcinomas, Epigenetics, vol.12, pp.19-26, 2017.

R. Kandimalla, A. A. Van-tilborg, L. C. Kompier, D. J. Stumpel, R. W. Stam et al., Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers, Eur Urol, vol.61, pp.1245-1256, 2012.

K. J. Livak and T. D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method, Methods, vol.25, pp.402-408, 2001.

N. Gangat, M. M. Patnaik, and A. Tefferi, Myelodysplastic syndromes: Contemporary review and how we treat, Am J Hematol, vol.91, pp.76-89, 2016.

M. Nieto, P. Demolis, E. Béhanzin, A. Moreau, I. Hudson et al., The european medicines agency review of decitabine (Dacogen) for the treatment of adult patients with acute myeloid leukemia: Summary of the scientific assessment of the committee for medicinal products for human use, Oncologist, vol.21, pp.692-700, 2016.

A. Biktasova, M. Hajek, A. Sewell, C. Gary, G. Bellinger et al., Demethylation therapy as a targeted treatment for human papillomavirus-associated head and neck cancer, Clin Cancer Res, vol.23, pp.7276-7287, 2017.

S. Prince, S. Carreira, K. W. Vance, A. A. Goding, and C. R. , Tbx2 directly represses the expression of the p21(WAF1) cyclin-dependent kinase inhibitor, Cancer Res, vol.64, pp.1669-1674, 2004.

J. J. Jacobs, P. Keblusek, E. Robanus-maandag, K. P. Lingbeek, M. Nederlof et al., Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers, vol.26, pp.291-299, 2000.

K. W. Vance, S. Carreira, G. Brosch, and C. R. Goding, Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas, Cancer Res, vol.65, pp.2260-2268, 2005.

Z. Harrelson, R. G. Kelly, S. N. Goldin, J. J. Gibson-brown, R. J. Bollag et al., Tbx2 is essential for patterning the atrioventricular canal and for morphogenesis of the outflow tract during heart development, Development, vol.131, pp.5041-5052, 2004.
URL : https://hal.archives-ouvertes.fr/hal-00311141

T. H. Lüdtke, C. Rudat, I. Wojahn, A. C. Weiss, M. J. Kleppa et al., Tbx2 and Tbx3 act downstream of shh to maintain canonical wnt signaling during branching morphogenesis of the murine lung, Dev Cell, vol.39, pp.239-253, 2016.

B. Zhu, M. Zhang, E. M. Williams, C. Keller, A. Mansoor et al., TBX2 represses PTEN in rhabdomyosarcoma and skeletal muscle, vol.35, pp.4212-4224, 2016.

K. L. Redmond, N. T. Crawford, H. Farmer, D. Costa, Z. C. et al., T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells, Oncogene, vol.29, pp.3252-3262, 2010.